AMD and Critical Metals Lead Today Wild Market Swings

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  06 Oct 2025
 

•   APP  
   
  -12.11%
•   CRML  
   
  -2.69%
•   DFLI  
   
  +4.41%
•   SKYE  
   
  -2.06%
•   SOPA  
   
  +18.30%

$AMD captured the spotlight with a stunning 23.65% surge to $203.71 on explosive volume of 235 million shares, more than five times its average. The catalyst? A blockbuster multi-year AI chip supply agreement with OpenAI that could generate tens of billions in annual revenue. Under the deal, OpenAI will deploy up to 6 gigawatts of AMD Instinct GPUs starting with a 1-gigawatt rollout in 2026, and the ChatGPT creator gains an option to take a 10% equity stake in the chipmaker. BofA wasted no time raising its price target from $200 to $250, while Wedbush analysts called the partnership a "major moment in the AI revolution."

$CRML rocketed 45.24% higher to $11.59 as shares of Critical Metals Corp attracted intense attention following reports of potential government involvement. Reuters initially suggested the Trump administration was eyeing a stake in the company, sending the stock soaring on volume nearly 30 times its daily average. While Bloomberg later reported the administration was not actually weighing such an investment, the stock maintained much of its gains after the company separately announced a $35 million PIPE agreement with a new fundamental institutional investor.

$SOPA delivered the session's most eye-popping percentage gain, skyrocketing 275.91% to $5.30 on enormous volume of 202 million shares. Society Pass Inc received bullish commentary from Ascendiant Capital Markets highlighting the company's impressive 46% year-over-year revenue growth in the second quarter of 2025. The analyst note specifically pointed to recent IPO activity as a driver of SOPA's valuation expansion, with today's trading volume nearly 1,000 times its typical daily average.

$SKYE suffered a devastating 60% plunge to $1.90 after Skye Bioscience reported that its CBeyond Phase 2a study of nimacimab monotherapy for weight loss failed to meet its primary endpoint. The 26-week trial results sent shockwaves through the biotech sector, as investors had been excited about novel obesity treatments following the success of GLP-1 drugs. Volume spiked to 15 million shares compared to a typical 365,000 as shareholders rushed for the exits.

$DFLI dropped 24.87% to $1.42 after Dragonfly Energy announced it priced an underwritten public offering of 20 million shares expected to generate approximately $25 million in gross proceeds. The dilutive offering came after the stock had already doubled, prompting profit-taking on volume of 84.76 million shares, nearly twice its average. The lithium battery manufacturer's fundraising suggests aggressive expansion plans but at the cost of existing shareholder equity.

$APP rounded out the major losers with a 14.03% decline to $587 after AppLovin faced cautious commentary from Wedbush analysts. Despite the stock remarkable run driven by its AI-powered advertising technology, the "ish views" from the influential research firm sparked profit-taking. Volume of 11.45 million shares exceeded its average as traders reassessed valuations in the high-flying ad-tech space, even as the company continues to be recognized for its exceptional return on equity.

View All Headlines